

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.usplo.gov

Fax Cover Sheet

Date: 29 Jun 2004				
To: Mary Kay	From: Patricia A. Duffy			
Application/Control Number: 10/076,634	Art Unit: 1645			
Fax No.: 202-408-4400	Phone No.: 571-272-0855			
Voice No.:	Return Fax No.: (703) 872-9306			
Re: 10/076,634	CC:			
☐ Urgent ☐ For Review ☐ For Comment ☐ For Reply ☐ Per Your Request				
Comments: To: Mary Kay,				
Attached is a copy of missing page 14 of the office action for the above recited Application number. If I can be of further help, please call met				
Thank you, Para Dy, Exr. Patricia Duffy				

Number of pages 2 including this page

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

10/076634				
SERIAL NUMBER FILING	G DATE	FIRST NAMED APPLICANT	A	TTORNEY DOCKETT NO.
		Γ	EX/	AMINER
		L		
		Γ	ART UNIT	PAPER NUMBER
		L		002904
		D	ATE MAILED:	
	EX	AMINER INTERVIEW SUMMARY RECO	RD	
All participants (applicant, applican	t's representative,	PTO personnel):		
(1) Mary Lay		(3)		
(2) Patricia Duffy		(4)		
Date of interview4/39/6				
		o □ applicant □ applicant's representative).		
		☐ No. If yes, brief description:		
Agreement	respect to some or	r all of the claims in question. $\ \square$ was not reached.		
Claims discussed:				
Ciairis discussed.				
Identification of prior art discussed	!			
				Norman - 1 - 1 - 11 - 11 - 11 - 11 - 11 - 11
			names MSYULL II	nducoleit
		d to if an agreement was reached, or any other comm		
that py 14 was me	ssing from 1	the last office action of acord	The sxamine	- fexal to
MS. Kay missing a	24 4 to	44 last office action of acold	-	
3	8			
(A fuller description, if necessary, a attached. Also, where no copy of	and a copy of the a	amendments, if available, which the examiner agreed which would render the claims allowable is available,	d would render the clai a summary thereof mu	ms allowable must be ust be attached.)
		separate record of the substance of the interview.		
Unless the paragraph below has b	een checked to inc	dicate to the contrary, A FORMAL WRITTEN RESPO OF THE INTERVIEW (e.g., items 1-7 on the reverse none month from this interview date to provide a stat	side of this form). If a	response to the last Office
Since the examiner's interpretation of the confidence of the	rview summary ab	pove (including any attachments) reflects a complete at Office action, and since the claims are now allowat tion. Applicant is not relieved from providing a separ	response to each of th	e objections, rejections and n is considered to fulfill the
box 1 above is also check	red.			
PTOL 413 (PEV 2 -93)		Examiner's Signa	ature W	*

Application/Control Number: 10/076,634

Art Unit: 1645

As to claim 21, the claim is uninterpretable, the claim recites obtaining the fusion protein by the process of claim 14 and releasing insulin therefrom, however, the fusion protein of claim 14 is not directed to an insulin fusion protein.

Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. *Process Control Corp. v. HydReclaim Corp.*, 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999). The term "signal sequence" in claims 2-5, is used by the claim to mean "a nucleic acid sequence that increases yield", while the accepted meaning is "a peptide present on proteins that are destined with to be secreted or the be membrane components. It is usually at the N terminus and normally absent from the mature protein. Normally refers to the sequence (ca 20 amino acids) that interact with signal recognition particle and directs the ribosome to the endoplasmic reticulum where co translational insertion takes place. "The term is indefinite because the specification does not clearly redefine the term and the term does not provide for the property of increasing yield.

Claim Rejections - 35 USC \$ 102 103

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 6, 9-15, 17, 22 and 23 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Dawson et al, WO 91/09125 published 27 June 1991.